Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 15,840 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: INFECTIONS Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM

NCT00137631
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Many Men, Many Voices (3MV)
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 30, 2026, 5:27 AM EDT
Not listed No phase listed Observational

SQuISH-COVID: A Pilot Study

NCT04372472
View directory record Official record
Conditions
Sepsis, COVID-19
Interventions
Not listed
Lead sponsor
Cytovale, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

NCT05044195
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years to 64 Years
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine

NCT00734175
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H6N1 Teal HK 97/AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 30, 2026, 5:27 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT04880109
View directory record Official record
Conditions
COVID-19
Interventions
APX-115, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

NCT00125099
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 5:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

NCT06230367
View directory record Official record
Conditions
HIV Infections
Interventions
Sexual health advocacy for guys, Healthy lifestyle control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
13 Years to 22 Years · Male only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 5:27 AM EDT
Completed No phase listed Observational

Early Short Course Corticosteroids in COVID-19

NCT04374071
View directory record Official record
Conditions
COVID, Pneumonia, Viral
Interventions
Methylprednisolone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

NCT00539864
View directory record Official record
Conditions
Influenza
Interventions
FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years to 64 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
Fresno, California • Hayward, California • Roseville, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 30, 2026, 5:27 AM EDT
Terminated Phase 4 Interventional Results available

Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock

NCT00535821
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Loma Linda, California • Worcester, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 30, 2026, 5:27 AM EDT
Withdrawn Not applicable Interventional

Steroids Helping Albuterol Responders Exclusively

NCT00798616
View directory record Official record
Conditions
Bronchiolitis
Interventions
prednisolone or methylprednisolone, placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Weeks to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 30, 2026, 5:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

NCT01453907
View directory record Official record
Conditions
Anthrax
Interventions
ETI-204, "Anthim", placebo
Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 5:27 AM EDT
Completed No phase listed Observational Results available

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

NCT05080192
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Not applicable Interventional Results available

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

NCT00672932
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2013 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

NCT00415493
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
Cold-dry air provocation, Warm-moist air provocation
Other
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

NCT01302847
View directory record Official record
Conditions
HIV Infections
Interventions
DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Weeks to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 30, 2026, 5:27 AM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

NCT02315638
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Tacere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Responses Induced by Different Licensed Influenza Vaccines

NCT00902278
View directory record Official record
Conditions
Immune Response
Interventions
Flulaval, Fluvirin, Fluzone, Fluarix, Afluria
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 30, 2026, 5:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

NCT02921997
View directory record Official record
Conditions
Avian Influenza, H1N1 Influenza, Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 30, 2026, 5:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

NCT01989897
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol
Drug
Lead sponsor
Bryan Martin, DO
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 5:27 AM EDT